The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Charles C Hsu; Joseph M Herman; Michele M Corsini; Jordan M Winter; Matthew D Callister; Michael G Haddock; John L Cameron; Timothy M Pawlik; Richard D Schulick; Christopher L Wolfgang; et al. (Profiled Authors: Timothy Pawlik; John Cameron; Joseph Herman; Christopher Wolfgang; Daniel Laheru; Richard Schulick)
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, MD, USA.
Annals of surgical oncology 2010;17(4):981-90.
BACKGROUND: Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant chemoradiation (CRT) may decrease survival compared with surgery alone. Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adenocarcinoma compared with surgery alone. MATERIALS AND METHODS: Patients with pancreatic adenocarcinoma at Johns Hopkins Hospital (n = 794, 1993-2005) and Mayo Clinic (n = 478, 1985-2005) following resection who were observed (n = 509) or received adjuvant 5-FU based CRT (median dose 50.4 Gy; n = 583) were included. Cox survival and propensity score analyses assessed associations with overall survival. Matched-pair analysis by treatment group (1:1) based on institution, age, sex, tumor size/stage, differentiation, margin, and node positivity with N = 496 (n = 248 per treatment arm) was performed. RESULTS: Median survival was 18.8 months. Overall survival (OS) was longer among recipients of CRT versus surgery alone (median survival 21.1 vs. 15.5 months, P < .001; 2- and 5-year OS 44.7 vs. 34.6%; 22.3 vs. 16.1%, P < .001). Compared with surgery alone, adjuvant CRT improved survival in propensity score analysis for all patients by 33% (P < .001), with improved survival when stratified by age, margin, node, and T-stage (RR = 0.57-0.75, P < .05). Matched-pair analysis demonstrated OS was longer with CRT (21.9 vs. 14.3 months median survival; 2- and 5-year OS 45.5 vs. 31.4%; 25.4 vs. 12.2%, P < .001). CONCLUSIONS: Adjuvant CRT is associated with improved survival after pancreaticoduodenectomy. Adjuvant CRT was not associated with decreased survival in any risk group, even in propensity score and matched-pair analyses. Further studies evaluating adjuvant chemotherapy compared with adjuvant chemoradiation are needed to determine the most effective combination of systemic and local-regional therapy to achieve optimal survival results.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Kristin J Redmond; Christopher L Wolfgang; Elizabeth A Sugar; Julia Ahn; Hari Nathan; Daniel Laheru; Barish H Edil; Michael A Choti; Timothy M Pawlik; Ralph H Hruban; et al.Annals of surgical oncology 2010;17(12):3112-9.
Bolanle Asiyanbola; Ana Gleisner; Joseph M Herman; Michael A Choti; Christopher L Wolfgang; Michael Swartz; Barish H Edil; Richard D Schulick; John L Cameron; Timothy M PawlikJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009;13(4):752-9.
A Chakravarthy; R A Abrams; C J Yeo; L T Korman; R C Donehower; R H Hruban; M L Zahurek; L B Grochow; S O'Reilly; H Hurwitz; et al.International journal of radiation oncology, biology, physics 2000;48(4):1089-96.
Appears in this Publication
Author of this Publication